Skip to content


Emend, Fosaprepitant Dimeglumine, Ivemend (fosaprepitant) is a small molecule pharmaceutical. Fosaprepitant was first approved as Emend on 2008-01-11. It has been approved in Europe to treat neoplasms and vomiting. It is known to target substance-P receptor.
Trade Name Ivemend
Common Name Fosaprepitant
Indication neoplasms, vomiting
Drug Class Tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists; phosphoro-derivatives
Get full access now